A prospective study of suramin-induced peripheral neuropathy

Brain

Volumn 119, Issue 6, 1996, Pages 2039-2052

  Chaudhry, V ^a,b   Eisenberger, M A ^a   Sinibaldi, V J ^a   Sheikh, K ^a   Griffin, J W ^a   Cornblath, D R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Guillain Barre syndrome; Prostate cancer; Suramin; Total neuropathy score; Toxic neuropathy

Indexed keywords

NUCLEOTIDYLTRANSFERASE INHIBITOR; SURAMIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEMYELINATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NERVE BIOPSY; NERVE CONDUCTION; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLASMAPHERESIS; POLYNEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; SURAL NERVE;

EID: 0030462307     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/119.6.2039     Document Type: Article

References (35)

1. Allen PD, Johnston DH, Macey MG, Williams NS, Newland AC. Modulation of CD4 by suramin. Clin Exp Immunol 1993; 91: 141-6.
2. Asbury AK, Arnason BOW, Karp HR, McFarlin DE. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 1978; 3: 565-6.
3. Berger AR, Schaumburg HH, Schroeder C, Apfel S, Reynolds R. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology 1992; 42: 1367-70.
4. Bitten RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, et al. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol 1995; 13: 2223-9.
5. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC. Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994; 35: 304-11.
6. Constantopoulos G, Rees S, Cragg BG, Barranger JA, Brady RO. Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat. Proc Natl Acad Sci USA 1980; 77: 3700-4.
7. Eisenberger MA. Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, et al. Suramin. an active drug for prostate cancer: interim observations in a phase I trial [see comments] [published erratum appears in J Natl Cancer Inst 1994; 86: 639-40]. J Natl Cancer Inst 1993; 85: 611-21. Comment in: J Natl Cancer Inst 1993; 85: 594-7.
8. Eisenberger MA. Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, et al. Suramin. an active drug for prostate cancer: interim observations in a phase I trial [see comments] [published erratum appears in J Natl Cancer Inst 1994; 86: 639-40]. J Natl Cancer Inst 1993; 85: 611-21. Comment in: J Natl Cancer Inst 1993; 85: 594-7.
9. Eisenberger MA, Sinibaldi VJ, Reyno LM, Sridhara R, Jodrell DI, Zuhowski EG, et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 1995; 13: 2174-86.
10. Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996; 39: 625-35.
11. Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy [see comments]. Arch Neurol 1992; 49: 612-16. Comment in: Arch Neurol 1994; 51: 234-6.
12. Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy [see comments]. Arch Neurol 1992; 49: 612-16. Comment in: Arch Neurol 1994; 51: 234-6.
13. Kantoff PW. New agents in the therapy of hormone-refractory patients with prostate cancer. [Review]. Semin Oncol 1995; 22 (1 Suppl 1): 32-4.
14. Karpati G, Carpenter S, Eisen AA, Wolfe LS, Feindel W. Multiple peripheral nerve entrapments. Arch Neurol 1974; 31: 418-22.
15. Kelly WK, Scher HI, Mazumdar M, Vlamis V. Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer [see comments]. J Clin Oncol 1993; 11: 607-15. Comment in: J Clin Oncol 1993; II: 596-7.
16. Kelly WK, Scher HI, Mazumdar M, Vlamis V. Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer [see comments]. J Clin Oncol 1993; 11: 607-15. Comment in: J Clin Oncol 1993; II: 596-7.
17. Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher HI. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995a; 13: 2208-13.
18. Kelly WK, Scher HI. Mazumdar M, Pfister D, Curley T, Leibertz C, et al. Suramin and hydrocortisone: determining dose efficacy in androgen-independent prostate cancer. J Clin Oncol 1995b; 13: 2214-22.
19. Kobayashi K, Yokes EE, Vogelzang NJ, Janish L, Soliven B, Ratain MJ. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 1995; 13: 2196-207.
20. La Rocca RV, Meer J, Gilliatt RW, Stein CA, Cassidy J, Myers CE, et al. Suramin-induced polyneuropathy. Neurology 1990; 40: 954-60.
21. Levine AM, Gill PS, Cohen J, Hawkins JG, Formenti SC, Aguilar S, et al. Suramin antiviral therapy in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105: 32-7.
22. McKhann GM, Cornblath DR. Griffin JW, Ho TW, Li CY, Jiang Z, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993; 33: 333-42.
23. Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, Broder S. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 1984; 226: 172-4.
24. Myers CE. La Rocca RV, Cooper MR, Danesi R, Jamis-Dow CA, Stein CA, et al. Role of suramin in cancer biology and treatment. 1991; 413-31.
25. Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, et al. Suramin: a novel growth factor antagonist with activity in hormone-related metastatic prostate cancer [see comments]. J Clin Oncol 1992; 10: 881-9. Comment in: J Clin Oncol 1992; 10: 875-7, 1984-6.
26. Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, et al. Suramin: a novel growth factor antagonist with activity in hormone-related metastatic prostate cancer [see comments]. J Clin Oncol 1992; 10: 881-9. Comment in: J Clin Oncol 1992; 10: 875-7, 1984-6.
27. Rees S. Membranous neuronal and neuroglial inclusions produced by intracerebral injection of suramin. J Neurol Sci 1978; 36: 97-109.
28. Rees S, Constantopoulos G, Barranger JA, Brady RO. Organomegaly and histopathology in an animal model of mucopolysaccharidosis induced by suramin. Naunyn Schmiedebergs Arch Pharmacol 1982; 319: 262-70.
29. Russell JW, Windebank AJ, Podratz JL. Role of nerve growth factor in suramin neurotoxicity studied in vitro. Ann Neurol 1994; 36: 221-8.
30. Schaumburg HH, Spencer PS. Toxic neuropathies. Neurology 1979; 29: 429-31.
31. Scher HI. Suramin: here to stay? [editorial; comment]. J Natl Cancer Inst 1993; 85: 594-7. Comment on: J Natl Cancer Inst 1993; 85: 611-21.
32. Scher HI. Suramin: here to stay? [editorial; comment]. J Natl Cancer Inst 1993; 85: 594-7. Comment on: J Natl Cancer Inst 1993; 85: 611-21.
33. Spencer PS, Schaumburg HH. Pathology of neurotoxic axonal degeneration. New York: Raven Press, 1978; 265.
34. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989; 7: 499-508.
35. Swift TR, McDonald TF. Peripheral nerve involvement in Hunter syndrome (mucopolysaccharidosis II). Arch Neurol 1976; 33: 845-6.